Recent Advances in Pharmacological Treatments of Adult Dermatomyositis
- 459 Downloads
Purpose of the Review
Dermatomyositis (DM) is an uncommon autoimmune disease that primarily affects the skin, muscle, and/or lungs, and remains a therapeutic challenge. We discuss recent studies evaluating efficacy of conventional treatments for clinically amyopathic DM (CADM), DM-associated interstitial lung (ILD) disease, and classic DM (CDM). We highlight several emerging new therapies with a focus on clinical trials, systematic reviews, and case series in the last 5 years.
Recent studies report a significant number of patients remain refractory to antimalarials and require second- and third-line agents. Effective treatment for DM-associated ILD can vary based on patient specific antibodies. CDM requires oral glucocorticoids; recent studies have evaluated the benefits of adjunctive therapies including methotrexate and calcineurin inhibitors. New therapies target cell populations or cytokines thought to drive disease pathogenesis.
Dermatomyositis is an autoimmune disease that remains challenging to treat. Many patients are refractory to conventional therapies, warranting the development and evaluation of new treatments.
KeywordsClinically amyopathic dermatomyositis Classic dermatomyositis Interstitial lung disease Therapeutics Treatment algorithms
Clinically amyopathic dermatomyositis
cyclic adenosine monophosphate
Idiopathic inflammatory myopathies
International Myositis Assessment & Clinical Studies Group
Interstitial lung disease
anti-melanoma differentiation-associated gene 5
rapidly progressive interstitial lung disease
tumor necrosis factor
visual analog scale
This project is supported by the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development and National Institutes of Health (National Institute of Arthritis and Musculoskeletal and Skin Diseases) R01AR071653 (VPW).
Compliance with ethical standards
The authors are employed by the University of Pennsylvania, which owns the copyright for the CDASI. VPW is the principal investigator of Lenabasum in DM.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 5.•• Pinard J, Femia AN, Roman M, Alsarheed A, Joyce C, Lin J, et al. Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers. JAMA Dermatol. 2019. https://doi.org/10.1001/jamadermatol.2018.5215 This study examined the systemic treatment of clinically amyopathic dermatomyositis and reported low response to antimalarial therapy despite it being a first-line agent in cutaneous DM. CrossRefGoogle Scholar
- 6.Callen JP, Wortmann RL. Dermatomyositis. Clin Dermatol. 2006;24(5):363–73. https://doi.org/10.1016/j.clindermatol.2006.07.001.CrossRefPubMedGoogle Scholar
- 7.•• Mainetti C, Beretta-Piccoli BT, Selmi C. Cutaneous manifestations of dermatomyositis: a comprehensive review. Clin Rev Allergy Immunol. 2017;53(3):337–56. https://doi.org/10.1007/s12016-017-8652-1 Excellent review covering epidemiology, pathogenesis, clinical manifestations, and treatment of cutaneous dermatomyositis. CrossRefPubMedGoogle Scholar
- 13.•• Callander J, Robson Y, Ingram J, Piguet V. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. Br J Dermatol. 2018;179(6):1248–55. https://doi.org/10.1111/bjd.14726 A systematic review of treatment of clinically amyopathic dermatomyositis reporting a majority of patients require more than one treatment due to refractoriness or side effects. CrossRefPubMedGoogle Scholar
- 14.•• Sunderkötter C, Nast A, Worm M, Dengler R, Dörner T, Ganter H, et al. Guidelines on dermatomyositis–excerpt from the interdisciplinary S2k guidelines on myositis syndromes by the German Society of Neurology. J Dtsch Dermatol Ges. 2016;14(3):321–38. https://doi.org/10.1111/ddg.12909 This report details guidelines of treatment for dermatomyositis in Germany as it pertains to skin or muscle disease. CrossRefPubMedGoogle Scholar
- 15.•• Kohsaka H, Mimori T, Kanda T, Shimizu J, Sunada Y, Fujimoto M, et al. Treatment consensus for management of polymyositis and dermatomyositis among rheumatologists, neurologists and dermatologists. Mod Rheumatol. 2019;29(1):1–9. https://doi.org/10.1111/1346-8138.14604 This report details treatment guidelines of dermatomyositis in Japan as it pertains to skin, lung, and muscle disease. CrossRefPubMedGoogle Scholar
- 17.• Galimberti F, Kooistra L, Li Y, Chatterjee S, Fernandez AP. Intravenous immunoglobulin is an effective treatment for refractory cutaneous dermatomyositis. Clin Experimental Dermatol. 2018;43(8):906–12. https://doi.org/10.1111/ced.13607 This retrospective study found IVIg to be an effective treatment for refractory cutaneous dermatomyositis, allowing for a decrease or discontinuation of immunosuppressive medication in 80% of patients. CrossRefGoogle Scholar
- 18.Bounfour T, Bouaziz JD, Bezier M, Cordoliani F, Saussine A, Petit A, et al. Clinical efficacy of intravenous immunoglobulins for the treatment of dermatomyositis skin lesions without muscle disease. J Eur Acad Dermatol Venereol. 2014;28(9):1150–7. https://doi.org/10.1111/jdv.12223.CrossRefPubMedGoogle Scholar
- 22.Hozumi H, Fujisawa T, Nakashima R, Yasui H, Suzuki Y, Kono M, et al. Efficacy of glucocorticoids and Calcineurin inhibitors for anti-aminoacyl-tRNA Synthetase antibody–positive polymyositis/dermatomyositis–associated interstitial lung disease: a propensity score–matched analysis. J Rheumatol. 2019;46(5):509–17. https://doi.org/10.3899/jrheum.180778.CrossRefPubMedGoogle Scholar
- 24.•• Barba T, Fort R, Cottin V, Provencher S, Durieu I, Jardel S, et al. Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun Rev. 2019;18(2):113–22. https://doi.org/10.1016/j.autrev.2018.07.013 This meta-analysis including 553 patients evaluated the efficacy of treatments used in the management of idiopathic inflammatory myositis associated interstitial lung disease. CrossRefPubMedGoogle Scholar
- 27.Johnson NE, Arnold WD, Hebert D, Gwathmey K, Dimachkie MM, Barohn RJ, et al. Disease course and therapeutic approach in dermatomyositis: a four-center retrospective study of 100 patients. Neuromuscul Disord. 2015;25(8):625–31. https://doi.org/10.1016/j.nmd.2015.04.013.CrossRefPubMedPubMedCentralGoogle Scholar
- 29.•• Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–8. https://doi.org/10.1016/S0140-6736(15)01021-1 Clinical trial in juvenile dermatomyositis reporting improved response with prednisone and ciclosporin or prednisone and methotrexate compared to prednisone alone. CrossRefPubMedGoogle Scholar
- 37.•• Saunders P, Tsipouri V, Keir GJ, Ashby D, Flather MD, Parfrey H, et al. Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials. 2017;18(1):275 The first randomized controlled trial to study the efficacy of rituximab as first-line therapy for connective tissue disease-associated interstitial lung disease.CrossRefGoogle Scholar
- 39.•• Tjärnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Studýnková JT, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. Ann Rheum Dis. 2018;77(1):55–62 A clinical trial evaluating the efficacy of abatacept in adult patients with dermatomyositis or polymyositis.CrossRefGoogle Scholar
- 41.Werth VP, Hejazi E, Pena SM, Haber JS, Okawa J, Feng R, Gabre K, Concha J, Cornwall C, Dgetluck N, Constantine S, White B. A Phase 2 Study of Safety and Efficacy of Anabasum (JBT-101), a Cannabinoid Receptor Type 2 Agonist, in Refractory Skin-Predominant Dermatomyositis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/a-phase-2-study-of-safety-and-efficacy-of-anabasum-jbt-101-a-cannabinoid-receptor-type-2-agonist-in-refractory-skin-predominant-dermatomyositis/. Accessed January 26, 2019.
- 46.Paik JJ, Albayda J, Tiniakou E, Koenig A, Christopher-Stine L. Study of Tofacitinib in Refractory Dermatomyositis (STIR): An Open Label Pilot Study in Refractory Dermatomyositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/study-of-tofacitinib-in-refractory-dermatomyositis-stir-an-open-label-pilot-study-in-refractory-dermatomyositis/. Accessed February 23, 2019.
- 54.Higgs BW, Zhu W, Morehouse C, White WI, Brohawn P, Guo X, et al. A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients. Ann Rheum Dis. 2014;73(1):256–62.CrossRefGoogle Scholar
- 56.•• Huard C, Gullà SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon β in dermatomyositis. Br J Dermatol. 2017;176(5):1224–30 Translational study linking the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) with the type 1 interferon pathway biomarkers, particularly interferon-β. CrossRefGoogle Scholar
- 61.Fernandez A. Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/interim-results-of-an-open-label-study-assessing-efficacy-and-safety-of-adrenocorticotropic-hormone-gel-for-treatment-of-refractory-cutaneous-manifestations-of-dermatomyositis/. Accessed March 18, 2019.